Full Text
Divergence of Evaluation of Orphan Drugs Between Regulators and Payers- Implications For Patient Access In US And EU

Abstract

Authors

I Ismailoglu S Duttagupta

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×